Notice

Notice reference number: 0960.15.08 Notice date: 18/08/2015

What's this about? Effective date: 18/08/2015

✓	ASX Trade		ASX 24										
✓	Trading		Clearing		Settlement								
	Operations		Technology		Market Data		Rules	✓	Compliance		Risk	✓	Other

Title

Paradigm Biopharmaceuticals Limited – Admission and Commencement of Official Quotation

Description

Paradigm Biopharmaceuticals Limited (Company) is expected to be admitted to the official list of ASX Limited (ASX) on Tuesday, 18 August 2015.

Official quotation of the Company's ordinary shares is expected to commence at 11.00 am AEST on Wednesday, 19 August 2015. The Company raised approximately $8,000,000 pursuant to the offer under the replacement prospectus dated 12 June 2015 (Prospectus) by the issue of 22,857,143 ordinary shares at an issue price of $0.35 per share.

Quoted Securities:	32,369,684 ordinary shares fully paid
ASX Code:	PAR
Time:	11.00 am AEST
Date:	19 August 2015
ASX Trade Abbreviation:	PARA BIO
ISIN:	AU000000PAR5
Home Branch:	Melbourne
Industry Classification:	3520 Pharmaceuticals, Biotechnology & Life Sciences
Registered and Corporate Office:	Level 2, 517 Flinders Lane Melbourne VIC 3000 Phone: (03) 9629 5566 Fax: (03) 8668 1716 Website: www.paradigmbiopharma.com
Communication person with ASX:	Kevin Hollingsworth
Share Registry:	Computershare Investor Services Pty Limited 452 Johnson Street Abbotsford VIC 3067 Phone: 1300 850 505 Fax: (03) 9473 2500

Balance Date:	30 June
CHESS:	Participating. The Company will also operate an issuer sponsored sub-register.
State of Incorporation:	Victoria
Activities:	Biopharmaceutical company focused on repurposing the drug, pentosan polysulphate sodium, for the lead clinical indication of bone marrow edema
Lead Manager and Underwriter:	Lodge Corporate Pty Ltd
ASX Restricted Securities:	33,915,618 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow for 24 months from the date of commencement of official quotation 876,603 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow for 12 months from 7 November 2014 923,077 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow for 12 months from 8 May 2015 19,495,238 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow for 12 months from 7 August 2015 3,023,812 options exercisable at $0.375 each on or before 7 August 2018 classified by ASX as restricted securities and to be held in escrow for 12 months from 7 August 2015 1,714,285 options exercisable at $0.50 each on or before 7 August 2018 classified by ASX as restricted securities and to be held in escrow for 12 months from 7 August 2015
Securities not quoted:	As above

What do I need to do and by when?

For further information, please refer to the Prospectus.

Need more information?

For further information, please call the Offer Information Line on 1300 723 167 (within Australia) or +61 3 9415 4277 (outside Australia) or visit www.paradigmbiopharma.com

Issued by
Emma Badhni

Disclaimer